Level 9, Suite 1, 68 Pitt Street
New South Wales
About Actinogen MedicalActinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other chronic neurodegenerative diseases. Actinogen Medical’s lead research candidate, Xanamem™, is a novel drug under development for the treatment of Alzheimer’s disease. Research recently demonstrated that increased cortisol, also known as the “stress hormone”, is associated with cognitive impairment, the development of beta-amyloid plaques and nerve death in the brain – the hallmarks of Alzheimer’s disease. Xanamem™, has been specifically designed to block the production of cortisol in the brain. Actinogen has successfully completed all the necessary early phase studies to confirm that Xanamem™ is well tolerated with an acceptable safety profile, and that it crosses the blood-brain-barrier in concentrations to adequately inhibit the excess production of cortisol in the hippocampus and frontal cortex of the brain, its primary site of action. Actinogen is well advanced in its plans for the Phase II “XanADu” efficacy and safety study with mild Alzheimer’s disease patients in the second half of 2016. This study will be run in Australia, the United Kingdom, and the United States with appropriate regulatory approvals.
CEO: Bill Ketelbey
Please click here for clinical trial information.
5 articles with Actinogen Medical
Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.
Actinogen Medical Limited recently announced positive results for Part A of its two-part double-blind placebo-controlled XanaMIA dose-ranging trial, which confirmed Xanamem's ability to rapidly enhance attention and working memory.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to announce it has enrolled the final patient into XanADu, its Phase II clinical trial of Xanamem in the treatment of patients with mild Alzheimer’s disease.